Zenas BioPharma, Inc. (ZBIO)
| Market Cap | 1.07B |
| Revenue (ttm) | 10.00M |
| Net Income (ttm) | -377.74M |
| Shares Out | 59.49M |
| EPS (ttm) | -8.44 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 535,232 |
| Open | 18.80 |
| Previous Close | 18.59 |
| Day's Range | 17.68 - 19.16 |
| 52-Week Range | 8.51 - 44.60 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 42.14 (+133.98%) |
| Earnings Date | Mar 16, 2026 |
About ZBIO
Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and FcγRIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a CTLA-4-Ig fusion protein designed to have an ext... [Read more]
Financial Performance
In 2025, Zenas BioPharma's revenue was $10.00 million, an increase of 100.00% compared to the previous year's $5.00 million. Losses were -$377.74 million, 140.6% more than in 2024.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for ZBIO stock is "Strong Buy." The 12-month stock price target is $42.14, which is an increase of 133.98% from the latest price.
News
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass., April 17, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the...
Zenas BioPharma Announces Pricing of Concurrent Public Offerings of 2.50% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $300.0 Million
WALTHAM, Mass., March 27, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas,” “Zenas BioPharma” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to be...
Zenas BioPharma Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032 and Common Stock
WALTHAM, Mass., March 26, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas,” “Zenas BioPharma” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to be...
Zenas BioPharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
- Obexelimab marketing applications for the treatment of IgG4-RD expected to be submitted to the FDA in Q2 2026 and the EMA in H2 2026 based on the Phase 3 INDIGO trial results - - Topline results of ...
Zenas BioPharma Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026
Obexelimab demonstrated strong efficacy and safety in IgG4-RD, with high physician and patient preference for its inhibitory, subcutaneous approach. Commercial launch is planned for the US and Europe, with a robust pipeline advancing in lupus, MS, and psoriasis.
Zenas BioPharma Announces Late-Breaking Platform Presentation of Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis at ACTRIMS Forum 2026
- Obexelimab met the primary endpoint with a 95% relative reduction in new gadolinium (Gd)-enhancing T1 lesions compared with placebo over weeks 8 and 12 (p=0.0009) -
Zenas BioPharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
WALTHAM, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the ...
Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the ...
Why Zenas BioPharma's Selloff Was Structurally Inevitable
Zenas BioPharma (NASDAQ: ZBIO) shares fell more than 50% in the last trading session following the release of Phase 3 results for obexelimab in patients with immunoglobulin G4-related disease (IgG4-RD...
Zenas BioPharma Touts Phase 3 Win, But Stock Crashes
Zenas BioPharma Inc. (NASDAQ: ZBIO) stock is trading lower on Monday after the company released results from the Phase 3 INDIGO trial of obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD).
Zenas BioPharma's immune disorder drug meets main goal in late-stage trial
Zenas BioPharma said on Monday its experimental drug cut the risk of disease flare-ups in a late-stage study of patients with a rare immune system-related condition that can damage organs over time.
Zenas BioPharma Transcript: Study Result
Obexelimab achieved a 56% reduction in IgG4-RD flare risk and met all key secondary endpoints in the phase III INDIGO trial, with a strong safety profile and over 70% of patients protected from flare. Its unique mechanism, at-home administration, and favorable cost structure position it as a potential first-line therapy.
Zenas BioPharma Announces Positive Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD)
- Obexelimab met the primary endpoint demonstrating a clinically meaningful and highly statistically significant 56% reduction in risk of IgG4-RD flare -
Zenas BioPharma's Partner, InnoCare Pharma, Announces Achievement of Primary Endpoint in Phase 2b Study of Orelabrutinib, a BTK Inhibitor, for Systemic Lupus Erythematosus
- Orelabrutinib is the first BTK inhibitor to demonstrate significant clinical activity in a Phase 2 clinical trial for SLE - - Zenas acquired the exclusive right to develop, manufacture and commercia...
Zenas BioPharma Transcript: Evercore ISI 8th Annual HealthCONx Conference
Major clinical milestones included phase III completion for obexelimab in IgG4-RD, strong phase II results in RMS, and ongoing lupus studies. Strategic deals expanded the pipeline and secured $300M in financing. Market opportunity in IgG4-RD is sizable, with product differentiation focused on at-home dosing and non-depleting B-cell inhibition.
Zenas BioPharma Transcript: Jefferies London Healthcare Conference 2025
The presentation highlighted a robust pipeline with imminent phase III results for IgG4-RD, strong phase II data in RMS, and a best-in-class BTK inhibitor advancing in progressive MS. Market research and trial design support confidence in clinical and commercial success.
Zenas BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update
- Obexelimab Phase 3 INDIGO trial topline results in Immunoglobulin G4-Related Disease (IgG4-RD) expected around year-end 2025 -
Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences
WALTHAM, Mass., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the ...
Zenas BioPharma Announces Positive Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis
- Obexelimab met primary endpoint with a 95% relative reduction in new gadolinium (Gd)-enhancing T1 lesions compared with placebo, p=0.0009 -
Zenas BioPharma Transcript: Status Update
Announced a global collaboration to acquire orelabrutinib and expand the autoimmune pipeline, with multiple late-stage and next-gen assets targeting significant commercial opportunities. Orelabrutinib's phase III MS trials are underway, and key data readouts for obexelimab and other programs are expected within the next year.
Zenas Bio inks potential $2 billion licensing deal with China's InnoCare for autoimmune drug
Zenas BioPharma said on Wednesday it has secured global rights to develop and commercialize an experimental drug from China-based InnoCare Pharma for multiple sclerosis and other autoimmune conditions...
Zenas BioPharma and InnoCare Pharma Announce License Agreement Granting Zenas Rights for Three Autoimmune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase 3 Development for Multiple Sclerosis
- Orelabrutinib, a highly selective CNS-penetrant, oral small molecule Bruton's Tyrosine Kinase (BTK) inhibitor with best-in-class potential now in Phase 3 development for progressive forms of Multipl...
Zenas BioPharma Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference
Obexelimab is advancing through pivotal trials in IgG4-related disease, MS, and SLE, with a focus on at-home subcutaneous administration and continuous dosing for improved outcomes. Key data readouts are expected over the next year, supported by strong capital and strategic partnerships.
Zenas BioPharma Transcript: Cantor Global Healthcare Conference 2025
Obexelimab is nearing a pivotal phase III readout in IgG4-related disease, with additional phase II trials in MS and SLE progressing. A $300M Royalty Pharma deal extends the cash runway and validates the market opportunity, while at-home dosing and a differentiated safety profile position the product competitively.